Fairmount Funds Management LLC - Significant Ownership

Signature - Title
Erin O'Connor - Chief Compliance Officer
Location
West Conshohocken, PA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Fairmount Funds Management LLC.

Significant Ownership of Fairmount Funds Management LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORKA ORUKA THERAPEUTICS, INC. Common Stock, $0.001 par value 19.99% $94.8M 8.51M Fairmount Funds Management LLC Mar 6, 2025
ATXS Astria Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% $36.6M 5.87M Fairmount Funds Management LLC Dec 31, 2024
IKT Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% $15.4M 7.02M Fairmount Funds Management LLC Dec 31, 2024
ELVN ENLIVEN THERAPEUTICS, INC. Common Stock, par value $0.001 per share 6.6% $65M 3.2M Fairmount Funds Management LLC Dec 31, 2024
ANAB ANAPTYSBIO, INC. Common Stock, par value $0.001 per share 0% $0 -$28.1M 0 -100% Fairmount Funds Management LLC Dec 31, 2024
KNSA Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares, nominal value $0.000273235 per share 0% $0 0 Fairmount Funds Management LLC Dec 31, 2024

Schedules 13D/G Reported by Fairmount Funds Management LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.